che-20230515x8k
false000001958400000195842023-05-152023-05-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):

May 15, 2023

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

     1-8351

  31-0791746

(State or other
jurisdiction of
incorporation)

(Commission File Number)

(I.R.S. Employer
Identification
Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202

(Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code:

(513) 762-6690

 

Title of each class

 

Trading symbol

Name of each exchange on which

registered

Capital stock $1 par value

CHE

NYSE

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12)

[_]     Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b))

[_]     Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  Emerging growth company [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]


Page 1 of 4


Item 5.07 Submission of Matters to a Vote of Security Holders

(a)On May 15, 2023, Chemed Corporation held its annual meeting of stockholders.

(b)Stockholders voted on the matters set forth below:

Item 1. Election of Directors. The following directors, who constitute the entire Board of Directors, were elected at the meeting by the votes indicated:

Nominee

For

Against

Abstentions

Broker non-votes

Kevin J. McNamara

13,177,032 

221,781 

16,901 

743,025 

Ron DeLyons

13,250,702 

155,701 

9,311 

743,025 

Patrick P. Grace

10,025,720 

3,295,348 

94,646 

743,025 

Christopher J. Heaney

13,026,990 

379,514 

9,210 

743,025 

Thomas C. Hutton

13,215,396 

192,523 

7,796 

743,025 

Andrea R. Lindell

12,704,541 

623,870 

87,304 

743,025 

Elaine McCarthy

13,392,362 

15,603 

7,749 

743,025 

John M. Mount Jr.

13,331,523 

75,000 

9,192 

743,025 

Thomas P. Rice

12,950,739 

376,753 

88,223 

743,025 

George J. Walsh III

11,270,147 

2,137,074 

8,493 

743,025 

Item 2. Ratification of Independent Accountants. The proposal to ratify the appointment of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the company’s independent accountants for the year ending December 31, 2023, was approved with the following votes:

Voted

For

13,715,097 

Against

436,826 

Abstain

6,818 

Broker non-votes

-

Item 3. Executive Compensation. The proposal to approve, on a non-binding basis, the Company’s executive compensation program, was approved with the following votes:

Voted

For

10,359,330 

Against

3,020,668 

Abstain

35,717 

Broker non-votes

743,025 


Page 2 of 4


Item 4. Frequency of advisory votes on executive compensation. The proposal to hold an advisory vote on frequency of advisory votes on executive compensation, was approved with the following votes:


Voted

One year

13,012,902 

Two years

118,686 

Three years

258,661 

Abstain

25,465 

Broker non-votes

743,025 

Item 5. Stockholder Proposal. The proposal requesting stockholder ratification of termination pay, was not approved with the following votes:

Voted

For

6,498,338 

Against

6,890,605 

Abstain

26,772 

Broker non-votes

743,025 

(c)Following the vote on frequency of stockholder advisory votes on executive compensation, the Board of Directors decided to hold a stockholder vote on executive compensation in the Company’s proxy materials each year until the next vote on frequency of stockholder advisory votes.

(d)Following her election, the Board of Directors determined that Eileen McCarthy is independent and appointed her to the Compensation/Incentive Committee.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   May 16, 2023

By:

/s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 4